Frontiers in Biomedical Technologies (Sep 2020)

Measurement of Radiation Exposure to Caregivers of Patients with Thyroid Diseases Treated with Iodine-131: A Review

  • Ali Abdulhasan Kadhim,
  • Peyman Sheikhzadeh,
  • Saeed Farzanefar,
  • Shima Yavari,
  • Majdi Mousa Jber,
  • Mohammad Reza Ay

DOI
https://doi.org/10.18502/fbt.v7i3.4622
Journal volume & issue
Vol. 7, no. 3

Abstract

Read online

This review paper aimed to examine radiation safety issues related to relatives as well as caregivers of patients with thyroid diseases treated with radioiodine (I-131). During I-131 therapy for thyroid disorders such as hyperthyroidism, patients receiving I-131 doses (200-800 MBq) emit radioactive radiations which pose a prospective risk to other people. Critical groups are patients’ visitors and families, especially children. Following the updated international guidelines, the doses received by members of the public as a proportion of the therapy of a patient have been decreased. The public annual dose limits are 1 mSv, although higher doses are permitted for adults in the patient’s family, provided that the maximum 5 mSv is not surpassed for 5 years. Without compliance with the current recommendations, extended hospitalizations for patients are essential. Family members should therefore limit close interactions with an individual for some duration following thyroid therapy with I-131.

Keywords